Your browser doesn't support javascript.
loading
Laboratory capacity assessments in 25 African countries at high risk of yellow fever, August-December 2018.
Johnson, Barbara Wilmot; Demanou, Maurice; Fall, Gamou; Betoulle, Jean-Luc; Obiekea, Celestina; Basile, Alison Jane; Domingo, Cristina; Goodman, Christin; Mossel, Eric; Reusken, Chantal; Staples, Erin; de Morais, Joana Filipa Machado; Neto, Zoraima; Paixão, Paula; Denon, Yves Eric; Glitho, Mariette; Mahinou, José; Kagone, Therese; Nakoune, Emmanuel; Gamougam, Kadidja; Simbu, Elisabeth Pukuta; Ahuka, Steve; Mombouli, Jean-Vivien; Goma-Nkoua, Cynthia; Adjogoua, Edgard Valery; Tayachew, Adamu; Beyene, Berhane; Sanneh, Bakary; Jarju, Modou Lamin; Mendy, Alphonse; Amelor, Dodzi Kofi; Ofosu-Appiah, Lawrence; Opare, David; Antwi, Lorreta; Adade, Rexford; Magassouba, N'Faly; Gomes, Sabado Fernandes; Limbaso, Samson; Lutomiah, Joel; Gbelee, Burgess; Dogba, John; Cisse, Issa; Idde, Zakou; Ihekweazu, Chikwe; Mba, Nwando; Faye, Ousmane; Faye, Oumar; Sall, Amadou Alpha; Koroma, Zikan; Juma, Manuela Alphonse.
Afiliación
  • Johnson BW; Scientific Laboratory Consulting, Laporte, Colorado, United States of America.
  • Demanou M; World Health Organization African Region Yellow Fever Laboratory, Ouagadougou, Burkina Faso.
  • Fall G; Centre Pasteur Cameroon, Yaoundé, Cameroon.
  • Betoulle JL; Institut Pasteur Dakar, Dakar, Senegal.
  • Obiekea C; Scientific Laboratory, Atlanta, Georgia, United States of America.
  • Basile AJ; National Reference Laboratory, Nigeria Centre for Disease Control, Abuja, Nigeria.
  • Domingo C; Centers for Disease Control and Prevention, Division of Vector-borne Diseases, Fort Collins, Colorado, United States of America.
  • Goodman C; Robert Koch Institute, Berlin, Germany.
  • Mossel E; Centers for Disease Control and Prevention, Division of Vector-borne Diseases, Fort Collins, Colorado, United States of America.
  • Reusken C; Centers for Disease Control and Prevention, Division of Vector-borne Diseases, Fort Collins, Colorado, United States of America.
  • Staples E; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • de Morais JFM; Centers for Disease Control and Prevention, Division of Vector-borne Diseases, Fort Collins, Colorado, United States of America.
  • Neto Z; Instituto Nacional de Investigacao em Saude, Luanda, Angola.
  • Paixão P; Instituto Nacional de Investigacao em Saude, Luanda, Angola.
  • Denon YE; Instituto Nacional de Investigacao em Saude, Luanda, Angola.
  • Glitho M; National Public Health Laboratory, Cotonou, Benin.
  • Mahinou J; National Public Health Laboratory, Cotonou, Benin.
  • Kagone T; National Public Health Laboratory, Cotonou, Benin.
  • Nakoune E; Scientific Laboratory Consulting, Laporte, Colorado, United States of America.
  • Gamougam K; World Health Organization African Region Yellow Fever Laboratory, Ouagadougou, Burkina Faso.
  • Simbu EP; Institute Pasteur, Bangui, Central African Republic.
  • Ahuka S; Hôpital General De Reference Nationale, N'Djamena, Chad.
  • Mombouli JV; National Institute for Biomedical Research, Kinshasha, Democratic Republic of Congo.
  • Goma-Nkoua C; National Institute for Biomedical Research, Kinshasha, Democratic Republic of Congo.
  • Adjogoua EV; Institut National de Santé Publique, Brazzaville, Republic of Congo.
  • Tayachew A; Institut National de Santé Publique, Brazzaville, Republic of Congo.
  • Beyene B; Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • Sanneh B; Ethiopian Public Health Institute, Virology and Rickettsiology Unit, Addis Ababa, Ethiopia.
  • Jarju ML; World Health Organization Laboratory, Ethiopia.
  • Mendy A; National Health Laboratory Services, Royal Victoria Teaching Hospital, Banjul, The Gambia.
  • Amelor DK; National Health Laboratory Services, Royal Victoria Teaching Hospital, Banjul, The Gambia.
  • Ofosu-Appiah L; National Health Laboratory Services, Royal Victoria Teaching Hospital, Banjul, The Gambia.
  • Opare D; National Public Health and Reference Laboratory, Public Health Division, Ghana Health Service, Korle-Bu, Accra, Ghana.
  • Antwi L; National Public Health and Reference Laboratory, Public Health Division, Ghana Health Service, Korle-Bu, Accra, Ghana.
  • Adade R; National Public Health and Reference Laboratory, Public Health Division, Ghana Health Service, Korle-Bu, Accra, Ghana.
  • Magassouba N; National Public Health and Reference Laboratory, Public Health Division, Ghana Health Service, Korle-Bu, Accra, Ghana.
  • Gomes SF; National Public Health and Reference Laboratory, Public Health Division, Ghana Health Service, Korle-Bu, Accra, Ghana.
  • Limbaso S; Laboratoire de Reference des Fièvres Hémorragiques, Conakry, Guinée.
  • Lutomiah J; Laboratoire National de Sante Publique, Bissau, Guinea-Bissau.
  • Gbelee B; Center for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Dogba J; Center for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Cisse I; National Public Health Reference Laboratory, National Public Health Institute of Liberia, Charlesville, Liberia.
  • Idde Z; National Public Health Reference Laboratory, National Public Health Institute of Liberia, Charlesville, Liberia.
  • Ihekweazu C; Institut National de Santé Publique Laboratoire de Fièvre Jaune, Bamako, Mali.
  • Mba N; Niamey National Hospital, Niamey, Niger.
  • Faye O; National Reference Laboratory, Nigeria Centre for Disease Control, Abuja, Nigeria.
  • Faye O; National Reference Laboratory, Nigeria Centre for Disease Control, Abuja, Nigeria.
  • Sall AA; Institut Pasteur Dakar, Dakar, Senegal.
  • Koroma Z; Institut Pasteur Dakar, Dakar, Senegal.
  • Juma MA; Institut Pasteur Dakar, Dakar, Senegal.
Pan Afr Med J ; 38: 402, 2021.
Article en En | MEDLINE | ID: mdl-34381546
ABSTRACT

INTRODUCTION:

accurate and timely laboratory diagnosis of yellow fever (YF) is critical to the Eliminate Yellow Fever Epidemics (EYE) strategy. Gavi, the Vaccine Alliance recognized the need to support and build capacity in the national and regional laboratories in the Global YF Laboratory Network (GYFLN) as part of this strategy.

METHODS:

to better understand current capacity, gaps and needs of the GYFLN laboratories in Africa, assessments were carried out in national and regional reference laboratories in the 25 African countries at high risk for YF outbreaks that were eligible for new financial support from Gavi.

RESULTS:

the assessments found that the GYFLN in Africa has high capacity but 21% of specimens were not tested due to lack of testing kits or reagents and approximately 50% of presumptive YF cases were not confirmed at the regional reference laboratory due to problems with shipping.

CONCLUSION:

the laboratory assessments helped to document the baseline capacities of these laboratories prior to Gavi funding to support strengthening YF laboratories.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fiebre Amarilla / Brotes de Enfermedades / Laboratorios Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Africa Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fiebre Amarilla / Brotes de Enfermedades / Laboratorios Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Africa Idioma: En Año: 2021 Tipo del documento: Article